AllSci News
FDA approves Rocket Pharmaceuticals' gene therapy Kresladi for severe pediatric leukocyte adhesion deficiency-I
The US FDA has granted accelerated approval to KRESLADI (marnetegragene autotemcel), an autologous hematopoietic stem cell-based gene therapy developed by...
FDA approves Corcept Therapeutics' Lifyorli for platinum-resistant ovarian cancer
The US FDA on March 25, 2026, approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adults with platinum-resistant...
FDA approves Denali Therapeutics' Avlayah for neurologic symptoms of Hunter syndrome in pediatric patients
The US FDA has granted accelerated approval to AVLAYAH (tividenofusp alfa-eknm), an enzyme replacement therapy developed by Denali Therapeutics for the...
EpiBiologics Launches Phase 1 Trial of EPI-326 EGFR-Degrading Bispecific Antibody in NSCLC and HNSCC
EpiBiologics has posted a Phase 1 clinical trial (NCT07462377) for EPI-326, a tissue-selective bispecific antibody targeting EGFR in patients with locally...
Kymera Therapeutics Advances KT-579 IRF5 Degrader Into Phase 1 Trial for Autoimmune Disease
Kymera Therapeutics has begun dosing participants in the first-ever clinical study of a drug designed to destroy interferon regulatory factor 5, a...
Unnatural Products and Novartis sign USD 1.8b macrocyclic peptide deal for cardiovascular disease
Unnatural Products, Inc. (UNP), a privately held biotechnology company headquartered in Santa Cruz, California, announced a research collaboration and...
Pilatus Biosciences doses first patient with anti-CD36 antibody PLT012 in advanced solid tumors
Pilatus Biosciences has dosed the first patient in a Phase 1 clinical trial of PLT012, a humanized monoclonal antibody that blocks CD36-mediated fatty acid...
Edding Genor's EDP167 Enters Phase II Trial in Growing Race to Silence ANGPTL3
Edding Genor Group Holdings Limited, the Hong Kong-listed specialty pharmaceutical company, has completed a first-in-human Phase I study of EDP167, a...
Mirador Therapeutics Launches Phase 1 Trial of MT-251 Bispecific Antibody Targeting TL1A and IL-23
Mirador Therapeutics has initiated dosing in a Phase 1 MT-251 clinical trial evaluating the safety, tolerability, pharmacokinetics, and immunogenicity of...
Structure Therapeutics' aleniglipron achieves 16.3% weight loss in phase 2 obesity trial
Structure Therapeutics (NASDAQ: GPCR), a San Francisco-based clinical-stage biopharmaceutical company, reported topline data from its Phase 2 ACCESS II...
Vanda Pharmaceuticals' imsidolimab BLA accepted by FDA for generalized pustular psoriasis treatment
Washington, D.C.-based Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced on February 25, 2026, that the US FDA has accepted its Biologics License...
Ascletis reports positive phase II data for ASC30 depot formulation in obesity treatment
Hong Kong-based Ascletis Pharma Inc. announced topline results from a US Phase II study of ASC30, a small molecule GLP-1 receptor agonist formulated as a...
China's NMPA approves Xdemvy for Demodex blepharitis, triggering $15M milestone payment to Tarsus
China's National Medical Products Administration has approved XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis, making...
Inhibikase's IB-001: First-in-Human Phase 1 Trial Targets Chronic Hepatitis B Treatment
A Novel Approach to Chronic Hepatitis B: Inside Inhibikase's First-in-Human IB-001 Trial
AnnJi Pharmaceutical's AJ201 Secures US FDA Fast Track Designation for Kennedy's Disease Treatment
FDA Grants Fast Track Designation to Promising Kennedy's Disease Treatment
The AllSci Brief
Free, systematic R&D and deal news. Daily.